Literature DB >> 31058796

Hypertension, white-coat hypertension and masked hypertension in Australia: findings from the Australian Diabetes, Obesity, and Lifestyle Study 3.

Geoffrey A Head1, Jonathan E Shaw1, David W Dunstan1, Neville Owen1, Dianna J Magliano1, Steve Chadban2, Paul Zimmet3.   

Abstract

BACKGROUND AND
METHOD: The Australian Diabetes, Obesity, and Lifestyle Study is a national, population-based examination of ∼11 000 adults with a third follow-up phase at 12 years. The aim was to use ambulatory blood pressure monitoring (ABPM) in a subsample (n = 508) of the main Australian Diabetes third follow-up cohort to determine the proportion with established, masked or white-coat hypertension in city and regional centers and the effectiveness of diagnosis and treatment.
RESULTS: Mean age was 58.9 years, BMI was 27.6 kg/m with 53% women. The mean clinic BP was 127/73 mmHg and mean 24-h BP was 121/73 mmHg. Using regression analysis estimations, the predicted ABPM daytime equivalent for the hypertension threshold values of 140/90 mmHg were 136/90 mmHg. There were 43% classified as hypertensive due to either ABPM 24-h more than 130/80 mmHg (17%) or taking antihypertensive therapy (25%). Ambulatory SBP/DBP were higher in men (24-h + 6.4/4.9 mmHg, P < 0.001) compared with women. There was only 3% with white-coat but 21% with masked hypertension indicating 24% misdiagnosis. Based on ABPM, 9% were treated and still hypertensive, which was three times more common in men (14%) than women (4%). Thus 36% had not reached target. There were no differences between urban and rural participants. Based on ABPM, nearly half the participants were hypertensive while only a quarter were taking antihypertensive therapy.
CONCLUSION: The findings highlight the importance of out-of-office BP assessments and the considerable gaps in effectively diagnosing and treating hypertension.

Entities:  

Mesh:

Year:  2019        PMID: 31058796     DOI: 10.1097/HJH.0000000000002087

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  5 in total

Review 1.  Evidence for and Against ACC/AHA 2017 Guideline for Target Systolic Blood Pressure of < 130 mmHg in Persons with Type 2 Diabetes.

Authors:  Jenny I Shen; Susanne B Nicholas; Sandra Williams; Keith C Norris
Journal:  Curr Cardiol Rep       Date:  2019-11-23       Impact factor: 3.955

2.  Potential Therapeutic Use of Neurosteroids for Hypertension.

Authors:  Geoffrey A Head; Kristy L Jackson; Cindy Gueguen
Journal:  Front Physiol       Date:  2019-12-12       Impact factor: 4.566

3.  Association between Systolic Blood Pressure and Diabetic Retinopathy in Both Hypertensive and Normotensive Patients with Type 2 Diabetes: Risk Factors and Healthcare Implications.

Authors:  Yu-Ting Li; Yi Wang; Xiu-Jing Hu; Jia-Heng Chen; Yun-Yi Li; Qi-Ya Zhong; Hui Cheng; Bedru H Mohammed; Xiao-Ling Liang; Jose Hernandez; Wen-Yong Huang; Harry H X Wang
Journal:  Healthcare (Basel)       Date:  2021-05-13

4.  Lowering blood pressure by changing lifestyle through a motivational education program: a cluster randomized controlled trial study protocol.

Authors:  Fakir M Amirul Islam; Elisabeth A Lambert; Sheikh Mohammed Shariful Islam; M Ariful Islam; Dip Biswas; Rachael McDonald; Ralph Maddison; Bruce Thompson; Gavin W Lambert
Journal:  Trials       Date:  2021-07-08       Impact factor: 2.279

5.  Factors associated with antihypertensive medication use and blood pressure control in a rural area in Bangladesh: baseline data from a cluster randomised control trial.

Authors:  Fakir M Amirul Islam; Elisabeth A Lambert; Sheikh Mohammed Shariful Islam; M Ariful Islam; Ralph Maddison; Bruce Thompson; Gavin W Lambert
Journal:  BMC Public Health       Date:  2021-12-23       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.